Cart (0 Items)
Your cart is currently empty.
View ProductsIt looks like you are visiting from outside the EU. Switch to the US version to see local pricing in USD and local shipping.
Switch to US ($)
| Size | 96T |
|---|---|
| Brand | ProteoGenix |
| Product type | Elisa assay kits |
| Product name | Sotrovimab ELISA kit |
|---|---|
| Delivery condition | Blue ice (+4°C) |
| Delivery lead time in business days | 3-5 days if in stocks, 3-5 weeks if production is needed |
| Storage condition | 4°C for short term (1 week), store at -20°C to -80°C for long term(1 year); Avoid repeated freeze-thaw cycles |
| Brand | ProteoGenix |
| Aliases /Synonyms | VIR-7831,GSK4182136,S309,GSK-4182136,CAS: 2423014-07-5 |
| Note | For research use only. |
| Immunogen | Sotrovimab |
| Assay type | Quantitative |
| Detection method | Colorimetric |
| Recovery | 80-120% |
The Sotrovimab ELISA kit is a powerful tool used in scientific research and clinical settings for the detection and quantification of the therapeutic target, sotrovimab. This kit is designed to specifically target and measure the levels of sotrovimab in various biological samples, providing valuable insights into its structure, activity, and potential applications.
Sotrovimab, also known as VIR-7831, is a monoclonal antibody that targets the spike protein of the SARS-CoV-2 virus. It is a fully human antibody, meaning that it is derived from human cells and has a similar structure to naturally occurring antibodies in the body. Sotrovimab is composed of two heavy chains and two light chains, each containing a unique sequence of amino acids that determine its specific binding properties.
The main mechanism of action of sotrovimab is its ability to bind to the spike protein of the SARS-CoV-2 virus, preventing its attachment and entry into host cells. This effectively neutralizes the virus and prevents it from replicating and causing infection. Sotrovimab has been shown to have high potency and specificity against the spike protein, making it a promising therapeutic target for COVID-19 treatment.
The Sotrovimab ELISA kit plays a crucial role in the development and evaluation of sotrovimab as a therapeutic target. It allows researchers to accurately measure the levels of sotrovimab in biological samples, such as blood or tissue, and monitor its effectiveness in neutralizing the SARS-CoV-2 virus. This information is essential in determining the optimal dosage and treatment regimen for sotrovimab.
Furthermore, the Sotrovimab ELISA kit can also be used to assess the pharmacokinetics of sotrovimab, which refers to how the body processes and eliminates the drug. This is important in understanding the drug’s absorption, distribution, metabolism, and excretion, which can affect its efficacy and safety.
In addition to its application in therapeutic targeting, the Sotrovimab ELISA kit is also widely used in research studies investigating the efficacy and safety of sotrovimab. Researchers can use this kit to compare the levels of sotrovimab in different biological samples, such as in patients with varying degrees of infection or in different animal models. This allows for a better understanding of how sotrovimab behaves in different scenarios and can aid in the development of more effective treatment strategies.
Moreover, the Sotrovimab ELISA kit can also be used in preclinical studies to assess the pharmacokinetics and pharmacodynamics of sotrovimab in animal models. This is crucial in the early stages of drug development to determine the appropriate dosage and potential side effects of the drug.
In conclusion, the Sotrovimab ELISA kit is a valuable tool in the study of sotrovimab as a therapeutic target for COVID-19. Its ability to accurately measure the levels of sotrovimab in biological samples provides important insights into its structure, activity, and potential applications. The Sotrovimab ELISA kit has the potential to greatly contribute to the development of effective treatments for COVID-19 and other diseases caused by the SARS-CoV-2 virus.
Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.
Reviews
There are no reviews yet.